106 related articles for article (PubMed ID: 38516593)
1. Targeting Tuberculosis: Novel Scaffolds for Inhibiting Cytochrome
Seitz C; Ahn SH; Wei H; Kyte M; Cook GM; Krause KL; McCammon JA
J Chem Inf Model; 2024 Jun; ():. PubMed ID: 38874541
[TBL] [Abstract][Full Text] [Related]
2. Antitubercular activity of 2-mercaptobenzothiazole derivatives targeting
Saha P; Sau S; Kalia NP; Sharma DK
RSC Med Chem; 2024 May; 15(5):1664-1674. PubMed ID: 38784457
[No Abstract] [Full Text] [Related]
3. Cyanide Insensitive Oxidase Confers Hydrogen Sulfide and Nitric Oxide Tolerance to
Nastasi MR; Caruso L; Giordano F; Mellini M; Rampioni G; Giuffrè A; Forte E
Antioxidants (Basel); 2024 Mar; 13(3):. PubMed ID: 38539916
[TBL] [Abstract][Full Text] [Related]
4. Targeting the cytochrome oxidases for drug development in mycobacteria.
Lee BS; Sviriaeva E; Pethe K
Prog Biophys Mol Biol; 2020 May; 152():45-54. PubMed ID: 32081616
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome
Saha P; Das S; Indurthi HK; Kumar R; Roy A; Kalia NP; Sharma DK
RSC Med Chem; 2024 Mar; 15(3):769-787. PubMed ID: 38516593
[TBL] [Abstract][Full Text] [Related]
6. Novel targets and inhibitors of the
Harikishore A; Mathiyazakan V; Pethe K; Grüber G
Expert Opin Drug Discov; 2023; 18(8):917-927. PubMed ID: 37332221
[TBL] [Abstract][Full Text] [Related]
7. Discovery of 1-hydroxy-2-methylquinolin-4(1H)-one derivatives as new cytochrome bd oxidase inhibitors for tuberculosis therapy.
Zhou Y; Shao M; Wang W; Cheung CY; Wu Y; Yu H; Hu X; Cook GM; Gong H; Lu X
Eur J Med Chem; 2023 Jan; 245(Pt 1):114896. PubMed ID: 36370551
[TBL] [Abstract][Full Text] [Related]
8. Targeting the menaquinol binding loop of mycobacterial cytochrome bd oxidase.
Harikishore A; Chong SSM; Ragunathan P; Bates RW; Grüber G
Mol Divers; 2021 Feb; 25(1):517-524. PubMed ID: 31939065
[TBL] [Abstract][Full Text] [Related]
9. Dual inhibition of the terminal oxidases eradicates antibiotic-tolerant Mycobacterium tuberculosis.
Lee BS; Hards K; Engelhart CA; Hasenoehrl EJ; Kalia NP; Mackenzie JS; Sviriaeva E; Chong SMS; Manimekalai MSS; Koh VH; Chan J; Xu J; Alonso S; Miller MJ; Steyn AJC; Grüber G; Schnappinger D; Berney M; Cook GM; Moraski GC; Pethe K
EMBO Mol Med; 2021 Jan; 13(1):e13207. PubMed ID: 33283973
[TBL] [Abstract][Full Text] [Related]
10. Exploiting the synthetic lethality between terminal respiratory oxidases to kill
Kalia NP; Hasenoehrl EJ; Ab Rahman NB; Koh VH; Ang MLT; Sajorda DR; Hards K; Grüber G; Alonso S; Cook GM; Berney M; Pethe K
Proc Natl Acad Sci U S A; 2017 Jul; 114(28):7426-7431. PubMed ID: 28652330
[TBL] [Abstract][Full Text] [Related]
11. Syntheses and Structure-Activity Relationships of
Hopfner SM; Lee BS; Kalia NP; Miller MJ; Pethe K; Moraski GC
Appl Sci (Basel); 2021 Oct; 11(19):. PubMed ID: 36698770
[TBL] [Abstract][Full Text] [Related]
12. Identification of 2-Aryl-Quinolone Inhibitors of Cytochrome
Jeffreys LN; Ardrey A; Hafiz TA; Dyer LA; Warman AJ; Mosallam N; Nixon GL; Fisher NE; Hong WD; Leung SC; Aljayyoussi G; Bibby J; Almeida DV; Converse PJ; Fotouhi N; Berry NG; Nuermberger EL; Upton AM; O'Neill PM; Ward SA; Biagini GA
ACS Infect Dis; 2023 Feb; 9(2):221-238. PubMed ID: 36606559
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
